

# Poisoning in Israel: Annual Report of the Israel Poison Information Center, 2017

Yedidia Bentur MD<sup>1</sup>, Yael Lurie MD<sup>1</sup>, Alfred Cahana MD<sup>1</sup>, Anna Bloom-Krasik MD<sup>1</sup>, Nona Kovler MD<sup>1</sup>, Gal Neuman MD<sup>1</sup>, Bella Gurevych MD<sup>1</sup>, Paul Sofer MD<sup>1</sup> and Wendy Klein-Schwartz PharmD MPH<sup>2</sup>

<sup>1</sup>Israel Poison Information Center, Rambam Health Care Campus, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

<sup>2</sup>Maryland Poison Center, Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD, USA

**ABSTRACT:** **Background:** The Israel Poison Information Center (IPIC), Rambam Health Care Campus, provides 24-hour telephone consultations on clinical toxicology and drug and reproductive toxicology information. It participates in research, teaching and regulatory activities, and provides laboratory services. In 2014, nurse specialists in poison information joined the IPIC. **Objectives:** To report the epidemiology of poison exposures in Israel.

**Methods:** We present computerized queries and a descriptive analysis of the medical records database of the IPIC for 2017.

**Results:** A total of 39,928 poison exposure cases were recorded, reflecting increases of 226.3% and 26.7% compared with 1995 and 2012, respectively. Children < 6 years of age were involved in 47.0% of cases; 80.4% of calls were made by the public and 17.8% by physicians; 74.2% of exposures were unintentional and 7.3% intentional. Pharmaceuticals were involved in 51.4% of cases, chemicals in 36.9%, bites and stings in 2.2%, and plants and mushrooms in 1.5%. Substances most frequently involved were analgesics, cleaning products, and antimicrobials. Clinical severity was moderate/major in 3.3%, mainly due to insecticides, drugs of abuse, and corrosives. Three fatalities were recorded (due to colchicine, organophosphates, and volatile substance inhalant abuse).

**Conclusions:** Poison exposures and poisonings have markedly increased in Israel, contributing substantially to morbidity. The IPIC prevented unnecessary referrals to emergency departments. Its database is a valuable national resource for collecting and monitoring poisonings and poison exposure cases. It can be used as a real-time surveillance system for the benefit of public health. It is recommended that reporting to the IPIC become mandatory, and its activities adequately supported by national resources.

*IMAJ* 2019; 21: 175–182A

**KEY WORDS:** poisoning, intoxication, epidemiology, poison center, Israel

growth in the number of chemicals introduced into the environment, workplace and home. Among these chemicals are medications, complementary medicine products, cleaning substances, pesticides, fertilizers, petroleum distillates, intermediates in chemical processes, and drugs of abuse [1]. The wide availability of chemicals and medications has led to increased exposure of humans and animals to potential poisons. An unavoidable result has been the increase in the number of poisonings, which have become the third cause of injury-related fatalities [1]. While these processes are paralleled by a continuous updating of the information on poisons and poisonings, several problems remain unresolved: namely, there is still insufficient awareness of the potential hazards of poisons, physicians are generally not adequately trained in clinical toxicology, and keeping pace with the increasing amount of information has not always been possible. Starting in the 1950s, poison information centers were established worldwide in order to improve patient care (the first in Chicago in 1953) [1,2]. Their initial objective was to provide product information to healthcare professionals. The same objective was the rationale for the Israel Ministry of Health's decision to establish the Israel Poison Information Center (IPIC) at Rambam Hospital in 1964. The current concept of poison centers and of the IPIC includes additional objectives such as providing first aid and triage advice to the community in cases of poisonings, consulting healthcare providers on the rational management of the poisoned patient, avoiding unnecessary referrals to healthcare facilities and hospitalizations, teaching clinical toxicology to healthcare providers, collecting epidemiologic data on incidence, severity and trends of poisoning, and providing information on how to prevent poisonings.

Like other poison centers worldwide, the IPIC provides telephone consultations in clinical toxicology to the general public and healthcare professionals 24 hours a day, as well as bedside consultations to the Rambam Health Care Campus. Other types of clinical consultations provided by the IPIC include drug information and assessment of the effects of drugs, chemicals, toxins, and radiation on pregnancy and lactation.

An integral part of the IPIC is its Clinical Toxicology and Pharmacology Laboratory, which was expanded four years ago to also include pharmacogenetics. This laboratory performs a

An extraordinary process of industrialization and technological advancement has occurred since the beginning of the twentieth century. This process has resulted in an exponential

variety of toxicological tests, therapeutic drug monitoring, and occupational bio-monitoring assays using immunochemistry, atomic absorption spectrophotometry, and various chromatographic technologies. Pharmacogenetic tests are performed by polymerase chain reaction (PCR) followed by DNA sequencing.

The clinical staff of the IPIC teaches clinical toxicology to healthcare professionals, is involved in research, and updates the commercial products database as well as national prevention and regulatory activities. It also plays an important role in national preparedness (e.g., for multi-casualty toxicological incidents). The IPIC clinical staff comprises physicians and nurses. Most of the physicians are board certified in Internal Medicine, Pediatrics, and Clinical Pharmacology, and received additional training in Clinical Toxicology. Prior to 2013, all clinical staff were physicians. The incorporation of nurses into the clinical staff was initiated by leaders of the IPIC and Rambam Health Care Campus. Recruitment, training, and utilization of nurses as poison information specialists reflect a relatively recent change in staffing. This program was approved and supported by the Ministry of Health. Experienced nurses, all of them with a masters' degree and graduates of an intensive care or emergency medicine course, received special theoretical and practical training from the IPIC physicians. These nurses began providing clinical toxicology consultations, mainly to the public, on 1 January 2014. The IPIC physicians and nurses do daily on-duty and on-call shifts. With nurses now on the IPIC team, another telephone line was added for the evening hours, the busiest shift, thus increasing IPIC accessibility. Compared with the pre-2013 era, this situation is closer to the situation in North America where first-line responders are poison information specialists (nurses or pharmacists), while trained clinical toxicologists (physicians) are engaged in bedside medicine and serve mainly as backup [3].

Information sources used by the IPIC include various computerized databases, textbooks and journals. Two types of computerized databases are used:

- Databases for toxicological medical records and for commercial products. These are designated tailored databases, characterized, maintained, and updated by the IPIC team. They facilitate quick searches and serve as powerful epidemiologic tools with a unique perspective. Until 2014, this database used an Access platform on SQL server. As of 2015, the IPIC has been working with a new database using Java Software and Oracle Database (Oracle Corporation, Redwood Shores, CA, USA). Developed by the Information Technology team of Rambam Health Care Campus, this program enables more online data entry by the IPIC staff at the time of the call.
- Toxicological information sources based on poison monographs, e.g., Micromedex Healthcare Series and RightAnswer (formerly Chemknowledge), and text-based search and retrieval (e.g., Toxnet).

The American Association of Poison Control Centers publishes annual reports of poison exposures [3]. This U.S. national database provides clinical information on a variety of poison exposures, stimulates research, and is cited in numerous articles. Similar reports from Israel were published for 1981, 2007, and 2012 [4-6].

The objective of the present report is to provide updated data on the epidemiology of poison exposures in Israel. Periodic reports of this kind are required for characterization of poisonings, understanding trends, and stimulation of research, and are essential for national decision-making.

## PATIENTS AND METHODS

This report analyzes data of all calls made to the IPIC and the clinical toxicological consultations provided during the year 2017. The IPIC serves the entire population of Israel, which numbers 8,797,900. It is the only poison center in Israel that serves both the general public and healthcare facilities 24 hours a day. Reporting to the IPIC is passive and not mandatory. Case records in this database – as in other national poison centers [3,7] – are from self-reported calls. They reflect information provided when the public or healthcare professionals report an actual or potential exposure.

The process of consultation includes assessment of the patient's condition and of the exposure, advice on first aid, survey of data, triage recommendation (e.g., referral to emergency department or community physician, no further medical assessment required), and management recommendations (e.g., evaluation, treatment, follow-up). Since poisoning is a medical emergency, time is of the essence and the consultation should be concise and quick while at the same time comprehensive. The main goal in the clinical toxicological consultation process is to provide practical information. Therefore, the consultation is tailored to the patient, not just to the substance.

Quality control of the clinical consultations is achieved by periodic reporting to the on-call physician during shifts, case conferences in which the previous day's activities are evaluated and discussed, establishing and updating management protocols, academic activities, and auditing the toxicological medical records.

All consultation data are recorded in a comprehensive structured form ("Medical toxicological record") that includes caller and patient demographic details, substance/s involved, route, site and circumstances of exposure, time elapsed until consultation, clinical manifestations in a system-oriented approach, evaluation (including laboratory confirmation of exposure whenever possible), management, and follow-up recommendations. Follow-up is performed for moderate to severely poisoned patients and for other cases whenever possible. The clinical severity of each case is graded as no effect, minor (e.g., minimally bothersome, self-limited), moderate (e.g., systemic,

more pronounced, and prolonged than minor manifestations while not life-threatening), major (e.g., life-threatening manifestations, significant disability or disfigurement), death, unknown or not applicable, according to previously published criteria [3,8]. The severity grading reflects the patient's condition at the time of consultation and may not represent peak effect or later deterioration. In addition, each case is classified into one of six main categories: chemicals, pharmaceuticals, biologicals (poisonous plants and venomous animals), miscellaneous (e.g., foreign body, batteries, radiation, thermometers, electrical injury), disease (poison exposures eventually diagnosed as unrelated disease), and "general information." Each case is then further classified according to a previously prepared list of classifications and sub-classifications available at the IPIC.

All data are entered and stored online by the specialist at the time of the call, or subsequently by a trained clerk, in a designated tailored database using Java Software and Oracle Database (Oracle Corporation, Redwood Shores, CA, USA). All records are subjected to routine quality control.

In order to obtain the epidemiological characteristics of poison exposures for the year 2017, computerized queries were conducted using the various fields of the toxicological medical record. The demographic and clinical characteristics retrieved included identification of caller title and healthcare facility, age and gender of the patient, time elapsed between exposure and call to the IPIC, route, site and circumstances (e.g., unintentional, intentional) of exposure, agents involved, severity of poisoning, and management recommendations. Data were subjected to descriptive analysis. The method of data collection and evaluation of IPIC consultations was previously published [5,6,9-14]. Comparisons with IPIC data prior to 2017 and with the 2017 data of the American Association of Poison Control Centers [3] were made whenever possible or relevant.

**RESULTS**

The IPIC recorded 39,928 poison exposure cases during 2017. Table 1 shows the growth in the number of poison exposure cases reported to the IPIC in relation to the growth of the Israeli population since 1995. Table 2 illustrates the various callers and sites of exposure. The majority of calls (80.4%) were from the public, and the most common site of exposure was the home. Compared with 2012, the number of calls from physicians in 2017 decreased by 4.8% (7483 and 7123, respectively). The number of calls made by hospital physicians decreased from 5235 to 5042 (3.7%) and by community physicians from 2345 to 2072 (11.6%). In the U.S., 24.4% of calls are from healthcare facilities [3] compared with 19.6% in Israel. Table 3 shows the age and gender distribution. Children and adolescents under 18 years of age accounted for 56.2% of cases; 39.8% involved adults. More cases involved females (52.7%) than males (42.4%); gender was unknown in 4.9%.

**Table 1.** Annual number of poison exposure cases reported to the IPIC

Year	Population served*	Poison exposures reported	Exposures per thousand population	Exposures per thousand population, USA [3]
1995	5,619,000	12,235	2.2	9.3
1996	5,759,400	16,695	2.9	9.3
1997	5,900,000	14,792	2.5	8.8
1998	6,041,400	15,712	2.6	8.7
1999	6,209,100	15,729	2.5	8.4
2000	6,369,300	16,687	2.6	8.0
2001	6,508,800	17,035	2.6	8.1
2002	6,631,100	18,775	2.8	8.2
2003	6,748,400	19,582	2.9	8.1
2004	6,869,500	22,602	3.3	8.3
2005	6,990,700	24,605	3.5	8.2
2006	7,116,700	24,218	3.4	8.0
2007	7,242,200	26,738	3.7	8.1
2008	7,412,200	28,198	3.8	8.1
2009	7,552,000	29,042	3.8	8.0
2010	7,695,100	26,981	3.5	7.6
2011	7,836,600	30,137	3.8	7.4
2012	7,984,500	31,519	3.9	7.2
2013	8,059,500	30,640	3.8	6.8
2014	8,215,700	36,740	4.4	6.7
2015	8,380,100	35,616	4.3	6.7
2016	8,546,000	36,751	4.3	6.6
2017	8,797,900	39,928	4.5	6.4

\*According to the data of the Central Bureau of Statistics, Israel <http://www.cbs.gov.il/publications18/yarhon1018/pdf/b1.pdf>; accessed November 14, 2018

**Table 2.** Site of caller and site of poison exposures

	Caller (%)*		Site of exposure (%)	
	Number	Percentage	Number	Percentage
Public**	32,095	(80.4)	Home	29,569 (74.1)
Physicians***	7123	(17.8)	Outdoors	1324 (3.3)
Nurses	365	(0.9)	Workplace	441 (1.1)
Medics	318	(0.8)	Healthcare facility	207 (0.5)
Veterinarians	27	(0.1)	Army	200 (0.5)
			School	299 (0.7)
			Agriculture	31 (0.1)
			Sea	51 (0.1)
			Industry	62 (0.2)
			Other/unknown	2159 (5.4)

\*Institutions: hospitals 5042 (12.6%), community clinics 2072 (5.2%), Magen David Adom in Israel (pre-hospital emergency medical service) 15 (0.04%)

\*\*23,317 (74.0%) in 2012, 19,427 (72.7%) in 2007, 5496 (37.2%) in 1997, and 544 (10%) in 1981

\*\*\*7483 (23.7%) in 2012, 6820 (25.5%) in 2007, 8457 (57.2%) in 1997, and 4353 (80%) in 1981

**Table 3.** Age and gender distribution of poison exposure cases

Age (years)	Males (% of age group)	Females (% of age group)	Unknown gender (% of age group)	Total (% of total exposures)
0–5	10,476 (61.9)	8078 (38.4)	213 (10.8)	18,767 (47.0)
6–12	1243 (7.3)	855 (4.1)	37 (1.9)	2135 (5.3)
13–17	597 (3.5)	816 (3.9)	21 (1.1)	1434 (3.6)
Unknown child	56 (0.3)	36 (0.2)	14 (0.7)	106 (0.3)
≥ 18	4317 (25.5)	10,448 (49.7)	117 (5.9)	14,882 (37.3)
Unknown adult	202 (1.2)	771 (3.7)	17 (0.9)	990 (2.5)
Unknown age	25 (2.3)	38 (0.2)	1551 (78.7)	1617 (4.0)
Total (% of total)	16,916 (42.4)	21,042 (52.7)	1970 (4.9)	39,928 (100%)

**Table 4.** Distribution of the routes of poison exposures

Route*	n	% of all cases	% of all routes
Ingestion/buccal	25,384	74.2	72.6
Inhalation/nasal	2691	7.9	7.7
Ocular	2011	5.9	5.8
Dermal	1633	4.8	4.7
Bite/sting	763	2.2	2.2
Parenteral	308	0.9	0.9
Rectal	328	1.0	0.9
Other/unknown	1845	5.4	5.3

\*Some patients were exposed through more than one route

The distribution regarding time elapsed from exposure to call was as follows: 52.3% within one hour, 6.6% between 1 and 2 hours, 9.8% between 2 and 8 hours, 6.6% between 8 and 24 hours, 2.9% more than 24 hours, and in 21.8% of cases the time was unknown or not relevant (e.g., inquiries on drug information or general information).

Table 4 shows the distribution of the routes of exposure. The most common route(s) were oral/buccal (74.2%), followed by inhalation/nasal (7.9%), ocular (5.9%), dermal (4.8%), and bite/sting (2.2%).

Table 5 shows the distribution of the circumstances of exposure. Unintentional exposures accounted for 29,608 cases: 94.5%, 92.5%, 56.7%, and 52.5% of cases in age groups < 6 years, 6–12 years, 13–17 years, and ≥ 18 years, respectively. Intentional exposures accounted for 2906 cases; 0.05%, 2.4%, 35.1%, and 14.9% of cases in age groups < 6 years, 6–12 years, 13–17 years, and ≥ 18 years, respectively. Drug and chemical information accounted for 6172 cases: 3.6%, 3.0%, 4.9%, and 26.8% of cases in age groups < 6 year, 6–12 years, 13–17 years, and ≥ 18 years, respectively.

The management sites recommended by the IPIC were: at site of exposure 52.5% (e.g., no need for referral to healthcare facility, no treatment required or only first-aid measures such as

**Table 5.** Distribution of circumstances of poison exposures

Circumstances	n (%)
<b>Unintentional</b>	
General <sup>a</sup>	16,842 (42.2)
Therapeutic error <sup>b</sup>	6006 (15.0)
Accident	1137 (2.8)
Misuse <sup>c</sup>	3061 (7.7)
Bite/sting	785 (2.0)
Food	429 (1.1)
Occupational	75 (0.2)
Environmental	175 (0.4)
Other/unknown	1098 (2.7%)
Total unintentional	29,608 (74.2)
<b>Intentional<sup>d</sup></b>	
Suicide	2306 (5.8)
Abuse	305 (0.8)
Malicious	85 (0.2)
Other/unknown	210 (0.6)
Total intentional	2906 (7.3)
<b>Drug information</b>	5310 (13.3)
Chemical Information	862 (2.2)
Unknown circumstances	1242 (3.1)

<sup>a</sup>Exposures that could not be classified otherwise. Refers mainly to pediatric exposures (e.g., curiosity and experimentation by young children)

<sup>b</sup>Unintentional incorrect use of a pharmaceutical (e.g., dose, route, wrong person, medication, indication, interaction). Refers to errors made by healthcare providers, parents or caregivers

<sup>c</sup>Unintentional improper or incorrect use of a non-pharmaceutical (chemical) substance

<sup>d</sup>Intentional: suicide, abuse, malicious

**Table 6.** Distribution of the clinical severity of poison exposure cases according to age groups

Severity	< 6 years n (% of age group)	6–12 years n (% of age group)	13–17 years n (% of age group)	≥ 18 years n (% of age group)	Unknown age n (% of unknown age)	Total n (% of total)
No effect	13,820 (76.6)	1194 (57.2)	513 (37.1)	3733 (36)	729 (47.2)	19,989 (59.8)
Minor	3142 (17.4)	740 (35.5)	717 (51.9)	5296 (51.02)	471 (30.5)	10,366 (31)
Moderate	121 (0.7)	49 (2.4)	75 (5.4)	547 (5.3)	60 (3.9)	852 (2.6)
Major	23 (0.1)	7 (0.3)	10 (0.7)	161 (1.6)	25 (1.6)	226 (0.7)
Death	0	0	0	1 (0.01)	2 (0.2)	4 (0.01)
Unknown	927(5.1)	97 (4.6)	67 (4.8)	643 (6.2)	256 (16.6)	1993 (6)

skin irrigation or dilution with water), emergency department 14.9% (e.g., referral to or observation/treatment in an emergency department was required), community clinics 11.4%, admission to hospital ward 2.6%, admission to intensive care unit 0.9%, and not applicable 17.5% (e.g., retrospective questions, prospective drug and chemical information inquiries, general information), and veterinarian 0.1%.

Table 6 shows the distribution of the clinical severity of poison exposures according to age groups. Table 7 shows the distribution of the clinical severity by circumstances of exposure. No effect or minor effect occurred in 76.1% of cases, with more severe outcomes occurring in 2.7%. Severe outcomes (moderate or major effect) occurred more frequently

**Table 7.** Distribution of clinical severity of poison exposure cases according to circumstances of exposure

Severity	Unintentional (% of unintentional)	Intentional (% of intentional)	Drug & chemical information (% of drug & chemical information)	Unknown (% of unknown)	Total (% of total exposures)
No effect	18,538 (62.6)	754 (26.0)	422 (6.7)	290 (23.3)	20,004 (50.1)
Minor	8253 (27.9)	1623 (55.9)	284 (4.5)	216 (17.4)	10,376 (26.0)
Moderate	428 (1.4)	292 (10.1)	42 (0.7)	92 (7.4)	854 (2.1)
Major	75 (0.3)	83 (2.9)	10 (0.2)	59 (4.8)	227 (0.6)
Death	1 (0.003)	0 (0.03)	0	2 (0.2)	3 (0.01)
Unknown	2304 (7.8)	151 (5.2)	242 (3.9)	580 (46.7)	3,277 (8.2)
N/A	0	0	5186 (82.5)	0	5,186 (13)

**Table 8.** Agent groups most frequently involved in single poison exposures

Chemicals	Pharmaceuticals	Biologic agents
Cleaning products	2679	3893
Personal care products	1561	2310
Corrosives	1272	1717
Insecticides	1219	1174
Bleaches	1106	970
Gases	987	832
Hydrocarbons	852	708
Scale Removers	819	690
Arts & office supplies	668	668
Essential oils	382	653
Alcohols	360	647
Adhesives	267	515
Rodenticides	106	440
Herbicides	77	432
Metals	66	421
		12

when the exposure was due to intentional reasons (13.0%) rather than unintentional (1.7%).

Three human fatalities were recorded during 2017, all were adults: a 27-year-old female due to organophosphate insecticide (unknown circumstances), a female due to colchicine (exact age and circumstances unknown), and a male due to volatile substance inhalant abuse (exact age unknown).

The various therapies and interventions recommended by the IPIC included: supportive measures, mechanical ventilation, decontamination (e.g., skin irrigation, dilution, activated charcoal, gastric lavage, whole bowel irrigation), enhanced elimination (e.g., multiple dose-activated charcoal, hemodialysis/hemoperfusion, urine alkalization), hyperbaric oxygen, gastroscopy, local treatment, and drugs and antidotes (e.g., antitetanus,  $\beta_2$  agonists, N-acetylcysteine, antihistamines,

**Table 9.** Substances most frequently involved in single poison exposures with moderate/major clinical severity\*

Substance	n	Most frequent agent	n
Insecticides	67	Organophosphates Pyrethrins	19 18
Drugs of abuse	64	Cannabis (THC)	10
Corrosives	61	Alkali	34
Gases	59	Irritant gases	29
Snakes	56	<i>Vipera palaestinae</i>	45
Analgesics	47	Acetaminophen	22
Sedatives/Hypnotics	42	Benzodiazepines	37
Alcohols	31	Ethanol	24
Antidepressants	31	SSRIs/SNRIs	13
Sympathomimetics	29	Methylphenidate	14
Anticonvulsants	23	Carbamazepine	6
Cleaning products	22	Detergents	8
Neuroleptics	22	Atypical neuroleptics	13
Cardiovascular drugs	20	Digoxin	14
Bleaches	19		
Hydrocarbons	19	Organic solvents	8
Plants	14	Digitalis-like Irritants	3 3
Spiders	11	<i>Loxosceles</i>	11
Scorpions	10	<i>Leiurus quinquestriatus</i>	10

\*Exposure to multiple pharmaceuticals occurred in an additional 190 moderate/major cases

corticosteroids, atropine, obidoxime, naloxone, flumazenil, H<sub>2</sub> antagonists/proton pump inhibitors, ethanol, fomepizole, antivenoms, glucagon, benzodiazepines, antiparkinsonians, calcium gluconate, digoxin Fab-fragments antibodies, methylene blue, sodium thiosulfate, and hydroxocobalamin).

The distribution of categories of all exposures (single and multiple substances) was as follows: pharmaceuticals (51.4%), chemicals (36.9%), bites and stings (2.2%), plants and mushrooms (1.5%), and miscellaneous (e.g., batteries, electrical injury, foreign bodies) (4.4%). Calls for general information and medical illness unrelated to poison exposures accounted for 3.4% of the cases.

Table 8 shows the agents most frequently involved in single-poison exposures. The most frequently involved single substances were analgesics, cleaning substances, antimicrobials, topical preparations, personal care products, corrosives, insecticides, and vitamins and supplements.

The most frequent poison exposures in children under 6 years old were to detergents (n=1457), acetaminophen (n=884), ibuprofen (n=785), silica gel (n=649), scale removers (n=549), bleaches (n=441), penicillins (n=438), and vitamin D (n=412).

Table 9 shows the agents most frequently involved in exposures with moderate to major clinical severity. The most

frequent exposures with moderate/major severity in children under 6 years old were to corrosives (n=23, alkali 13), insecticides (19, pyrethroids 5), cleaning products (15, detergents 5), sympathomimetic (10,  $\beta_2$  agonists 5), bleach (6), plants (6, irritants 2), and hydrocarbons (5, petroleum distillates 4).

Table 10 presents a summary of single-substance poison exposure cases by IPIC categories, classifications, and sub-classifications. More detailed data are available but are not presented due to space limitations.

### DISCUSSION

Our data show a 226% and 27% increase in poison exposure cases reported to the IPIC in the past 23 and 5 years, respectively, and an increase of 104% and 15%, respectively, in penetrance (poison exposures per 1000 population). The population increased by 58% and 11%, respectively. Although the current data are similar to the U.S. report, the penetrance per 1000 population is 4.5 (6.4 in the USA), which is 30% lower than in the U.S. [3].

Eighty percent of calls to the IPIC were made by the public, unlike the situation in the past: 74.0%, 73.0%, 34.7%, and 10% in 2012, 2007, 1995, and 1981, respectively. The nurses who joined the IPIC as specialists in poison information improved the availability of the IPIC to the public, therefore contributing tremendously to the increase in calls from the public. This trend of increased calls from the public should be encouraged, since many poison exposures (mainly pediatric and in the home) are asymptomatic or of mild severity and can be managed at home with IPIC follow-up, as needed. Thus, rational triage by poison centers can prevent unnecessary referrals to healthcare facilities, prevent unnecessary evaluations and treatments, reassure the victim and family, and reduce health expenditures [15-21].

A decrease of 15.8% in physicians' calls was observed over the last 20 years. Hospital physicians' calls decreased by 3.7%, whereas calls from community physicians decreased by 11.6%.

**Table 10.** Summary of poison exposure cases by IPIC categories, classifications and sub-classification.

The numbers refer to exposures to a single agent. The actual number of exposures in each category classification or sub-classification might be higher because of additional multiple exposures

**[A] Chemicals**

<b>Adhesives</b>	267	Glyphosate	43
Contact glue	81	Paraquat	5
Cyanoacrylate	77	Other/unknown	25
White glue	40	<b>Hydrocarbons</b>	852
Other/unknown	69	Acetone	224
<b>Alcohols</b>	361	Halogenated hydrocarbons	9

Ethanol	303	Paints, solvent-based	65
Ethylene glycol	22	Petroleum distillates	267
Isopropanol	5	Solvents	200
Methanol	7	Other/unknown	87
Glycols, other	2	<b>Insecticides</b>	1219
Other/unknown	22	Carbamates	34
<b>Aldehydes</b>	13	Methyl bromide	1
Formaldehyde	7	Mixed insecticides	149
Other/unknown	6	Organochlorines	1
<b>Arts &amp; office supplies</b>	668	Organophosphates	82
Correction fluid	35	Pyrethrins	540
Crayons	115	Other/unknown	412
Ink	263	<b>Metals</b>	66
Plasticine	80	Lead	10
Other/unknown	175	Mercury	30
<b>Asbestos</b>	6	Metal fume fever	2
<b>Bleaches</b> (e.g., hypochlorite)	1106	Other/unknown	24
<b>Cleaning products</b>	2679	<b>Miscellaneous</b>	2289
Deodorizers	259	Aquarium products	13
Detergents	1,853	Cigarettes	86
Waxes	8	E-cigarettes	11
Other/unknown	559	Fire extinguishers	55
<b>Corrosives</b>	1272	Food additives	2
Acid	307	Insect repellents	206
Alkali	681	Paints, water-based	98
Hydrofluoric acid	6	Silica gel	724
Phenol	9	Light stick	294
Quaternary ammonium	10	Other/unknown	800
Other/unknown	259	<b>Multiple chemicals</b>	173
Cyanide	3	<b>Personal care products</b>	1561
		Hair treatment	276
<b>Essential oils</b>	382	Cosmetics	222
Fertilizers and growth regulators	51	Perfumes and colognes	125
Fungicides	4	Soaps	248
<b>Gases</b>	987	Other/unknown	690
Asphyxiants	105	<b>Pesticides, other</b>	14
Carbon monoxide	18	<b>Rodenticides</b>	106
Freons	14	Anticoagulants	80
Hydrogen sulfide	7	Other/unknown	26
Irritants	643	<b>Scale removers</b>	819
Smoke	127	<b>Unknown</b>	162
Other/unknown	73	<b>Total chemicals: 15,138 (37.9%)</b>	
<b>Herbicides</b>	78		
Carbamates	3		
Chlorophenoxy compounds	2		

[B] Pharmaceuticals

<b>Analgesics</b>	3952	Antifungal	110	GHB	2	<b>Minerals</b>	433	<b>Sympathomimetics</b>	970
Acetaminophen	1352	Antiparasitic	312	Hallucinogenic amphetamines	5	Calcium	11	Amphetamine derivatives	4
Antimigraine	66	Antituberculosis	2	LSD	4	Fluoride	5	Beta 2 agonists	346
Aspirin	99	Antiviral	105	MDMA	23	Iron	389	Dietary amphetamines	7
Dipyron	377	Cephalosporines	251	Opioids	24	Zinc	2	Methylphenidate	392
Ibuprofen	1198	Macrolides	199	Synthetic cannabinoids	14	Other/unknown	26	Mixed inhaled (beta 2 + steroid)	15
Mixed analgesics	201	Penicillins	1011	Other/unknown	82	<b>Miscellaneous</b>	770	Nasal/Eye drops	37
NSAIDs	396	Quinolones	91	<b>Eye/ear/nose/throat preparations</b>	832	Allopurinol	5	Theophylline	2
Opioids	149	Sulfonamides	15	<b>Gastrointestinal drugs</b>	690	Antileukotrienes	72	Other/unknown	167
Tramadol	43	Tetracyclines	51	Antacids	140	Antiparkinson	29	<b>Topical preparations</b>	1723
Other/unknown	71	Other/unknown	160	Antidiarrheal	75	Colchicine	43	Analgesics	118
<b>Anesthetics</b>	137	<b>Antineoplastic</b>	52	Antiemetics	92	Dietary (non-amphetetamine)	2	Antihistamines	51
General	20	Methotrexate	25	Antispasmodic	40	Hypolipidemic	62	Antimicrobials	432
Local	113	Other/unknown	17	Antispasmodic	40	Mouthwash	92	Disinfectants	397
Other/unknown	4	<b>Cardiovascular</b>	425	H <sub>2</sub> antagonists	50	Oral hypoglycemics	105	Mixed preparations	167
<b>Anticholinergics</b>	76	ACE inhibitors & ARBs	83	Laxatives	85	Other/unknown	360	Pediculocides	122
Atropine	41	Alpha-blockers	28	Proton pump inhibitors	116	Multiple pharmaceuticals	2235	Other/unknown	436
Benzhexol	1	Antiarrhythmics	16	Other/unknown	92	<b>Muscle relaxants</b>	6	<b>Vaccines</b>	65
Other/unknown	34	Beta blockers	125	<b>Hormones</b>	708	<b>Neuroleptics</b>	353	<b>Veterinary drugs</b>	26
<b>Anticoagulants</b>	98	Ca channel blockers	63	Eltroxin	140	Atypicals	204	<b>Vitamins and supplements</b>	1190
Heparin	1	Digoxin	24	Insulin	24	Butyrophenones	9	A+D	6
Low molecular weight heparin	12	Nitrates	5	Oral contraceptives	363	Phenothiazines	72	B12	254
Warfarin	26	Vasodilators	5	Other/unknown	181	Other/unknown	68	D	494
Other/unknown	59	Vasopressors	28	<b>Immunosuppressants</b>	35	<b>Sedatives/hypnotics</b>	653	Folic acid	187
<b>Anticonvulsants</b>	303	Other/unknown	48	Azathioprine	11	Benzodiazepines	509	Multivitamins	148
Barbiturates	10	<b>Cold &amp; cough preparations</b>	517	Cyclosporine	5	Zolpidem/zopiclone	59	Other/unknown	101
Carbamazepine	64	<b>Complementary medicine products</b>	440	Tacrolimus	1	Other/unknown	85	<b>Total pharmaceuticals:</b>	<b>21,042 (52.7%)</b>
Lamotrigine	60	Botanicals	154	Other/unknown	18				
Levetiracetam	27	Dietary supplements	85						
Phenytoin	16	Homeopathic	81						
Topiramate	9	Mixed preparations	23						
Valproic acid	83	Other/unknown	97						
Other/unknown	34	<b>Contrast media</b>	89						
<b>Antidepressants</b>	669	<b>Corticosteroids</b>	339						
Cyclic	63	Inhaled	109						
Lithium	24	Systemic	164						
MAO inhibitors	5	Topical	61						
SSRIs & SNRIs	521	Other/unknown	5						
Other/unknown	56	<b>Diuretics</b>	35						
<b>Antihistamines</b>	651	Furosemide	9						
Astemizole/terfenadine	2	Thiazides	15						
Fexofenadine	56	Other/unknown	11						
Loratadine/desloratidine	185	<b>Drugs of abuse</b>	249						
Other (e.g., chlorpheniramine, promethazine)/ unknown	408	Amphetamine derivatives	9						
<b>Antimicrobials</b>	2321	Cannabis (THC, including medical cannabis)	67						
Aminoglycosides	14	Cathinone derivatives	2						
		Cocaine	17						

[C] Biologic agents

<b>Bites &amp; stings</b>	262	<b>Scolopendra</b>	92	<b>Plants</b>	568
Animal bites	39	<b>Scorpions</b>	160	Anticholinergic (e.g., <i>Datura</i> )	33
Insect stings	64	<b>Snakes</b>	167	Digitalis-like (e.g., <i>Oleander</i> )	74
Other/unknown	159	<i>Echis coloratus</i>	6	Irritants (e.g., <i>Arum</i> )	218
<b>Aquatic creatures</b>	64	<i>Vipera palaestinae</i>	100	Palm	8
Fish	16	Other/unknown	61	Other/unknown	235
Jellyfish	25	<b>Spiders</b>	54	<b>Mushrooms</b>	48
<i>Plotosus lineatus</i>	6	Latrodectus	4	Cholinergics	2
Scombrototoxin	1	Loxosceles	19	GI irritants	3
Sea urchin	3	Other/unknown	31	Other/unknown	43
Tetrodotoxin	1			Unknown	25
Other/unknown	12			<b>Total biologic agents: 1504 (3.8%)</b>	
<b>Hymenoptera</b>	64				
Bees	34				
Wasps	19				
Other/unknown	11				

**[D] Miscellaneous agents**

Food, contaminated/poisoning	629
Foreign bodies	378
Radiation	100
Thermometers	161
Batteries	183
Electrical injury	12
Other/unknown	348
<b>Total miscellaneous: 1811 (3.6%)</b>	

**[E] Other**

Disease*	1135
General information**	822

\*Cases with suspected poison exposure diagnosed by the clinical toxicologist as an unrelated disease

\*\*Enquiries unrelated to poison exposure or drug/chemical information

These trends might be explained by the “fee for service” system that discourages physicians from consulting the IPIC (as indicated by physicians calling the IPIC). Another possible reason is the increased availability of the IPIC and increased awareness of the public to its services, resulting in lower self-referrals to healthcare facilities. It should be emphasized that the toxicological consultation provided by the IPIC has never been withheld or delayed because of payment issues.

It is known that poison centers contribute markedly to the rational care of the poisoned patient and reduce healthcare costs [15-20]. Therefore, it is of utmost importance that the Ministry of Health fully support all costs of the IPIC (e.g., tenures, operational budget) and cancel the “fee for service” system. This will encourage physicians to consult with experts in clinical toxicology and improve the care of the acutely poisoned patient. In 2013, the IPIC initiated a project of nurses practicing as poison center specialists, similar to the situation in North America. The project was approved and supported by the Israel Ministry of Health. After theoretical and practical training, the nurses were integrated in the IPIC service. They provide toxicological consultations to the public under the supervision of the IPIC clinical toxicologists, and will soon begin answering calls from physicians. With the addition of nurses to staff, the patterns of IPIC work changed. More staff (physician and nurse) is now available during the busiest shifts, enabling operating two phone lines at a time, resulting in increased accessibility of the IPIC. The increase in call volume since 2013 likely reflects this greater accessibility. There was close to a 27% increase in calls from 2013 to 2017, which is much higher than the increase in population over that period. Interestingly, the call volume to IPIC continues to increase, while the opposite trend has been noted in the U.S. since around 2008.

As in our 2012 report [6], the most frequent exposures were to pharmaceuticals, followed by chemicals, bites and stings, and

plants and mushrooms. The five groups of substances most frequently involved in single-poison exposures were analgesics, cleaning products, antimicrobials, topical preparations, and personal care products. The five groups of substances most frequently involved in moderate to major exposures were insecticides, drugs of abuse, corrosives, gases, and snake bites. It should be noted that the number of drug information calls increased by 56.4% compared with our 2012 data; most of these calls came from the public [6]. This increase reflects the national role of the IPIC as a drug information source as well. We assume that it may also indicate better availability and utilization of the IPIC by the public.

About 56% of poison exposures were in children, 47% in children under 6 years of age. The severity of exposures in this young age group is less than in adolescents and adults, probably due to limited exposures (e.g., usually to one substance, small dose) and early recognition in contrast to exposures to multiple agents and deliberate self-poisonings in older patients [8]. The most common exposures in children under 6 years old were to analgesics, cleaning products, miscellaneous chemicals, vitamins and supplements, and personal care products. Corrosives, insecticides, bleach, plants, hydrocarbons, cleaning products, and sympathomimetics were mostly involved in moderate to major cases in young children.

**LIMITATIONS OF THE REPORT**

The IPIC data rely on passive reporting and reflect only information provided by the caller, such that some exposures may go unreported. Therefore, the data may not directly identify the overall incidence and trend of poisonings in Israel. It should be noted that aside from IPIC there is no other national registry of poisonings in Israel. The method of operation of the IPIC limits its ability to verify the accuracy of every report. The grading of severity reflects the patient’s condition at the time of consultation rather than the peak effect, thus possibly underestimating to some extent the true severity. These limitations are common to other national poison centers, including in the U.S. [3].

**CONCLUSIONS**

The number of poison exposures reported to the IPIC has grown continuously and dramatically since its inception in 1964. Poisoning continues to be a significant health problem. The IPIC provides specific and expert means to rationalize and improve the care of the poisoned patient. The IPIC database represents a valuable national resource to collect and monitor poisoning exposures in Israel. These data should and have been utilized to identify hazards early, focus on prevention education, guide and stimulate clinical research, direct training, assist in preparedness, and detect chemical/bioterrorism incidents. IPIC data should be used to support regulatory actions (e.g., prompt product reformulations, repackaging, recalls, and bans), contribute to post-marketing surveillance, and moni-

tor the implications of marketing of over-the-counter (OTC) medications.

In order to reach all these targets, the following is recommended: mandatory reporting to the IPIC, cancellation of the “fee for service” system, and adequate support of the IPIC. The latter can be achieved by increasing funding from the Ministry of Health with participation of healthcare facilities, pharmaceutical and consumer products companies, and possibly also of the general public.

**Acknowledgment**

We thank Mrs. Vered Steiner and Ms. Galit Soryano for their most valuable contribution to data collection, secretarial assistance and their unfailing dedication.

We also thank the nurses who joined the IPIC for their dedicated and professional work: Orit Granat, Iris Levdo, Taleb Moed, Maisar Salameh, and Dina Takachenko.

**Correspondence**

**Dr. Y. Bentur**

Director, Israel Poison Information Center, Rambam Health Care Campus, P.O. Box 9602, Haifa 3109601, Israel

**Phone:** (972-4) 777-2725

**Fax:** (972-4) 777-2092

**email:** d\_bentur@rambam.health.gov.il

**References**

1. Wax P. Historical principles and perspectives. In: Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR, eds. *Goldfrank's Toxicologic Emergencies*. 10th edn. New York: McGraw-Hill, 2015: 1-15.
2. Daly FFS, Murray LM, Little M, Dart RC. Specialized centers for the treatment of poisoned patients. In: Dart RC, ed. *Medical Toxicology*. 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2004: 6-9.
3. Gummin DD, Mowry JB, Spyker DA, Brooks DE, Osterhaler KM, Banner W. 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report. *Clin Toxicol* December 2018, <http://doi.org.10.1080/15563650.2018.1533727>.

4. Aloufy A, Raikhlin-Eisenkraft B, Taitelman U. Poisoning in Israel in 1981. *Harefuah* 1983; 105 (7): 155-8. (Hebrew)
5. Bentur Y, Lurie Y, Cahana A, et al. Poisoning in Israel: Annual Report of the Israel Poison Information Center, 2007. *IMAJ* 2008; 10 (11): 749-56.
6. Bentur Y, Lurie Y, Cahana A, et al. Poisoning in Israel: Annual Report of the Israel Poison Information Center, 2012. *IMAJ* 2014; 16 (11): 686-92.
7. Hoffman RS. Understanding the limitations of retrospective analyses of poison center data. *Clin Toxicol* 2007; 45 (8): 943-5.
8. Persson HE, Sjöberg GK, Haines JA, Pronczuk de Garbino J. Poisoning severity score. Grading of acute poisoning. *J Toxicol Clin Toxicol* 1998; 36 (3): 205.
9. Bentur Y, Raikhlin-Eisenkraft B, Lavee M. Toxicological features of deliberate self-poisonings. *Hum Exp Toxicol* 2004; 23 (7): 331-7.
10. Bentur Y, Cohen O. Dipyrrone overdose. *J Toxicol Clin Toxicol* 2004; 42 (3): 261-5.
11. Bentur Y, Raikhlin-Eisenkraft B, Galperin M. Evaluation of antivenom therapy in *Vipera palaestinae* bites. *Toxicon* 2004; 44 (1): 53-7.
12. Kozer E, Mordel A, Haim SB, Bulkowstein M, Berkovitch M, Bentur Y. Pediatric poisoning from trimedoxime (TMB4) and atropine automatic injectors. *J Pediatr* 2005; 146 (1): 41-4.
13. Finkelstein Y, Wahl MS, Bentur Y, et al. Universal versus selective iron supplementation for infants and the risk of unintentional poisoning in young children: a comparative study of two populations. *Ann Pharmacother* 2007; 41 (3): 414-19.
14. Bentur Y, Layish I, Krivoy A, et al. Civilian adult self injections of atropine-trimedoxime (TMB4) auto-injectors. *Clin Toxicol* 2006; 44 (3): 301-6.
15. Bindl L, Ruchardt J, Pfeiffer A, Kowalewski S, Lentze MJ. Effect of a German Poison Control Center on health care cost reductions in harmless exposure cases. *Vet Hum Toxicol* 1997; 39 (1): 48-50.
16. Kelly NR, Ellis MD, Kirkland RT, Holmes SE, Kozinetz CA. Effectiveness of a poison center: impact on medical facility visits. *Vet Hum Toxicol* 1997; 39 (1): 44-8.
17. Kearney TE, Olson KR, Bero LA, Heard SE, Blanc PD. Health care cost effects of public use of a regional poison control center. *West J Med*. 1995; 162 (6): 499-504.
18. Chafee-Bahamon C, Lovejoy FH Jr. Effectiveness of a regional poison center in reducing excess emergency room visits for children's poisonings. *Pediatrics* 1983; 72(2): 164-9.
19. King WD, Palmisano PA. Poison control centers: can their value be measured? *South Med J* 1991; 84 (6): 722-6.
20. Miller TR, Lestina DC. Costs of poisoning in the United States and savings from poison control centers: a benefit-cost analysis. *Ann Emerg Med* 1997; 29 (2): 239-45.
21. Elamin MEMO, James DA, Holmes P, et al. Reductions in emergency department visits after primary healthcare use of the UK National Poisons Information Service. *Clin Toxicol* 2018; 56 (5): 342-7.